About 30 Mg Paclitaxel Injection IP
Spotlight your oncology treatment protocol with our top-rated, peerless 30 Mg Paclitaxel Injection IP. Unlock ultimate clinical efficacy in managing ovarian cancer, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma. This lustrous solution-clear, colorless to pale yellow and viscous-comes as a sterile, single-use, preservative-free 5 ml glass vial enclosed in a secure carton. Manufactured in strict compliance with IP/BP/USP standards, it requires careful dilution and intravenous infusion using non-PVC equipment. Handle with utmost caution as per cytotoxic guidelines. Store below 25C, away from light. Discover world-class quality with every dose.
Competitive Edge & Applications
Our 30 Mg Paclitaxel Injection IP offers premium competitive advantages thanks to its superior purity, preservative-free composition, and strict adherence to international pharmacopoeial standards. Intended for advanced chemotherapy protocols, it serves specialists in hospitals, oncology clinics, and research centers. Its robust efficacy supports a wide commercial range-spanning treatment for ovarian, breast, and lung cancers, as well as AIDS-linked Kaposi's sarcoma-making it an indispensable pharmaceutical for healthcare providers.
Supply, Pricing, and Market Reach
Experience premium supply reliability with our 30 Mg Paclitaxel Injection IP, offered at a competitive list price and shipped in secure packaging. Flexible payment terms cater to institutional buyers, ensuring seamless procurement and prompt dispatch. Our distribution network covers the main domestic market across India, meeting pharmaceutical needs for hospitals, exporters, and traders. Trust in our commitment to deliver excellence, every shipment, every time.
FAQ's of 30 Mg Paclitaxel Injection IP:
Q: How should 30 Mg Paclitaxel Injection IP be prepared and administered?
A: The injection must be diluted with appropriate intravenous fluids and administered only as an intravenous infusion using non-PVC containers and tubing equipped with a 0.22 micron microporous filter.
Q: What precautions are necessary during the handling and administration process?
A: This cytotoxic drug should be handled following strict cytotoxic guidelines. Use must occur under qualified medical supervision, with resuscitation facilities readily available.
Q: When is the use of this product contraindicated?
A: The 30 Mg Paclitaxel Injection IP is contraindicated in individuals with hypersensitivity to Paclitaxel or any of its formulation excipients.
Q: Where should 30 Mg Paclitaxel Injection IP be stored to maintain potency?
A: It should be stored below 25C, protected from light, and not frozen. Proper storage ensures stability and effectiveness throughout its 24-month shelf life.
Q: What is the primary clinical indication for this injection?
A: This medicine treats ovarian cancer, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma, as indicated in approved protocols.
Q: How is disposal managed for this cytotoxic product?
A: Disposal of any unused or spent Paclitaxel Injection IP must fully comply with local cytotoxic safety regulations to ensure environmental protection and safety.
Q: What are the benefits of choosing this Paclitaxel Injection over alternatives?
A: The injection offers peerless safety, sterility, and efficacy, with a premium preservative-free composition and compliance with top pharmacopoeial standards for trusted treatment results.